NUVB

Nuvation Bio Inc. (NUVB) Economic Moat Analysis (2026)

Invetso Score: 3.2/10 — Weak · Last Updated: 2026-08-01

Overall Score

Profitability Returns

Gross margin is very high at 93.9%, but operating margin (-81.0%), EBITDA margin (-74.8%), and net margin (-88.2%) remain deeply negative.

Returns are still poor, with ROIC at -20.7%, ROE at -49.7%, and ROA at -20.1%, indicating no demonstrated economic moat through superior returns.

Balance Sheet Financial Resilience

Liquidity remains strong with a current ratio of 8.37x and cash ratio of 2.98x, giving the company substantial near-term flexibility.

Leverage is manageable, with debt-to-equity at 0.99x and net debt to EBITDA near flat at 0.05x, but negative operating cash flow still limits resilience.

Valuation Market Expectations

The market is still pricing in significant growth, with EV/Sales at 12.7x and price-to-sales at 12.7x despite negative earnings and cash flow.

Negative free cash flow and negative EBITDA make earnings-based valuation metrics unhelpful, reinforcing a stretched valuation profile.

Moat Durability Competitive Position

There is no clear evidence of pricing power or durable operating leverage yet, as high gross margins have not translated into positive operating profits.

The business appears to be in an early or investment-heavy phase, so any moat assessment remains speculative until returns and cash generation improve.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Nuvation Bio Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →